title: Macrophage activation syndrome in an inadequately treated patient with systemic onset juvenile idiopathic arthritis.
abstract: Macrophage activation syndrome is a rare and potentially life threatening complication of childhood rheumatic disorders. It is described most commonly with systemic onset juvenile idiopathic arthritis (soJIA). The major clinical manifestations are non-remitting fever, hepatosplenomegaly, lymphadenopathy, bleeding diathesis, altered mental status and rash and may mimic a fl are of soJIA. The characteristic laboratory findings are leucopenia, thrombocytopenia and dramatic elevation of urinary beta2 microglobulin. Corticosteroids and cyclosporine are the drugs commonly used in its management. Early diagnosis and prompt treatment can be life saving. We report a case of 12 year old female child with inadequately treated systemic onset juvenile idiopathic arthritis who developed fatal macrophage activation syndrome. The diagnosis and management of macrophage activation syndrome are discussed.
authors.affiliation: Department of Pediatrics, Maulana Azad Medical College, University of Delhi, New Delhi, India. drmonicajuneja@gmail.com
authors.forename: M
authors.initials: M
authors.lastname: Juneja
authors.forename: R
authors.initials: R
authors.lastname: Jain
authors.forename: D
authors.initials: D
authors.lastname: Mishra
mesh_terms: D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D002648:Child; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D055501:Macrophage Activation Syndrome / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D018570:Risk Assessment; D012720:Severity of Illness Index; D017211:Treatment Failure
chemical_list: D018501:Antirheumatic Agents; D009288:Naproxen